{"id":22280,"date":"2025-01-25T11:54:13","date_gmt":"2025-01-25T16:54:13","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=journal_article&p=22280"},"modified":"2025-08-19T11:59:43","modified_gmt":"2025-08-19T15:59:43","slug":"safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/","title":{"rendered":"Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study"},"content":{"rendered":"

Objectives<\/strong> \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD), whether COVID-19 vaccines (Monovalent BNT162b2) were associated with adverse events of special interest (AESI) or health care utilization.<\/p>\n

Methods<\/strong> \u2014 Using health administrative databases, all children\/youth with JIA or IBD who received at least one vaccine were identified from November 2020 to December 2021 with follow-up until August 31, 2022. Self-controlled case series analyses were used to determine the relative incidence rates (RIR) of events in any 3-week period [AESI, Emergency Department (ED) visits, hospitalizations] and in any 1-month period [specialist visits] post-vaccine compared to control periods.<\/p>\n

Results<\/strong> \u2014 We studied 1629 JIA and 1050 IBD patients. In the JIA cohort, the median age at vaccination was 12.0 years [Interquartile range (IQR): 10.0 to 14.0], and the median disease duration was 4.3 years (IQR: 2.0 to 7.5). By December 2021, 67.1% (n\u2005=\u20051093) received two doses and 24.1% (n\u2005=\u2005393) received three doses. In the IBD cohort, the median age at vaccination was 13.0 (IQR: 11.0 to 14.0) with a median disease duration of 2.4 years (IQR: 1.1 to 4.8). Fifty-four percent (n\u2005=\u2005565) received two doses and 36.3% (n\u2005=\u2005381) received three doses. During risk periods, AESI was rarely reported. Relative to control periods, JIA and IBD patients demonstrated similar rates of hospitalizations [JIA: RIR: 0.76 (95% confidence interval [CI]: 0.25 to 2.33), IBD: RIR: 0.64 (95% CI: 0.29 to 1.41)], ED visits [JIA: RIR: 1.11 (95% CI: 0.77 to 1.59), IBD: RIR: 0.93 (95% CI: 0.61 to 1.43)], and specialist visits [JIA: RIR: 1.06 (95% CI: 0.89 to 1.26), IBD: RIR: 0.56 (95% CI: 0.22 to 1.43)].<\/p>\n

Conclusions<\/strong> \u2014 Overall, this study demonstrates the safety of the BNT162b2 vaccine in children\/youths with JIA and IBD, with no associated increase in AESI or health care use.<\/p>\n","protected":false},"excerpt":{"rendered":"

Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD), whether COVID-19 vaccines (Monovalent BNT162b2) were associated with adverse events of special interest (AESI) or health care utilization. Methods \u2014 Using health administrative databases, all children\/youth with JIA or IBD who received at […]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[16,62,39,46],"migration-helper-qa-sample-set":[],"class_list":["post-22280","journal_article","type-journal_article","status-publish","hentry","topic-children-and-young-people","topic-health-services-research","topic-infectious-diseases","topic-internal-medicine"],"acf":{"citation":"Lee JJY, Bernatsky S, Benchimol EI, Kwong JC, Li Q, Yeung RSM, Widdifield J. Paediatr Child Health<\/em>. 2025; 30(4):305-311.","source_url":"https:\/\/doi.org\/10.1093\/pch\/pxae101","ices_scientist":[1174,1149,1122],"site":[6733],"research_program":[6746],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":"","previous_url":""},"yoast_head":"\nICES | Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study<\/title>\n<meta name=\"description\" content=\"Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD),\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study\" \/>\n<meta property=\"og:description\" content=\"Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD),\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-19T15:59:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\\\/\",\"name\":\"ICES | Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2025-01-25T16:54:13+00:00\",\"dateModified\":\"2025-08-19T15:59:43+00:00\",\"description\":\"Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD),\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study","description":"Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD),","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study","og_description":"Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD),","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-08-19T15:59:43+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/","name":"ICES | Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2025-01-25T16:54:13+00:00","dateModified":"2025-08-19T15:59:43+00:00","description":"Objectives \u2014 To evaluate among Ontario children and youth (<16 years old) with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD),","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/safety-and-health-care-utilization-following-covid-19-vaccination-bnt162b2-among-children-and-youth-with-juvenile-idiopathic-arthritis-and-inflammatory-bowel-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: a population-based study"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/22280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1122"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1149"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1174"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=22280"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=22280"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=22280"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=22280"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=22280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}